Abstract 1059P
Background
Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that form postnatally in non-lymphoid tissues and arise under pathological conditions. However, the clinical implications of localization and maturation stage of TLS in clear cell renal cell carcinoma (ccRCC) remain to be elucidated.
Methods
Immunohistochemistry and multispectral fluorescent were used to evaluate the TLS heterogeneity along with TME cell-infiltrating characterizations. We comprehensively assessed the prognostic and immunological implications of the TLS heterogeneity in 625 patients with ccRCC from multiply cohorts. Associations between TLS heterogeneity and immunologic activities were assessed by the quantification of immune cells infiltration.
Results
TLS typically comprises B-cell follicles with germinal centers and are surrounded by T-cell zones and dendritic cells. TLS infiltrates were identified in 34.2% of the ccRCC samples. A higher proportion of early TLS was found in peritumoral TLS, while intratumoral TLS mainly comprised secondary follicle-like. Kaplan-Meier analyses indicated that the presence of intratumoral TLS markedly correlated with both superior progression-free survival PFS and OS, while the presence of peritumoral TLS showed the opposite predictive trends for outcomes. Notably, presence of TLS, especially intratumoral TLS and mature TLS (namely SFL-TLS, with CD23+ germinal center) significantly correlated with better clinical outcomes and objective reflection rate for ccRCC patients receiving immunotherapies. Interestingly, in ccRCC samples with the presence of peritumoral TLS enriched with primary follicle-like TLS, the proportion of PD-L1+ tumor-associated macrophages and Treg infiltration in the peritumoral regions increased prominently, showing a typical suppressive TME characterizations.
Conclusions
In conclusion, this study for the first time revealed the implications of TLS localization and maturation heterogeneity on the clinical outcomes and immunological status and responses of ccRCC, allowing the identification of immunophenotypes and the improvement of immunotherapeutic effectiveness for ccRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1353P - Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations
Presenter: Jamie Feng
Session: Poster session 19
1354P - Beyond the common mutation: Examining chemotherapy success in uncommon EGFR mutations
Presenter: Chien-Chung Lin
Session: Poster session 19
1355P - Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib
Presenter: Marta Brambilla
Session: Poster session 19
1356P - 10-year survivors treated with tyrosine kinase inhibitor for advanced non-small cell lung cancer
Presenter: Yu Tanaka
Session: Poster session 19
1357P - Bevacizumab improved prognosis for advanced EGFR mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
Presenter: YuanLiang Zhou
Session: Poster session 19
1358P - Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
Presenter: Ernest Nadal
Session: Poster session 19
1359P - Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients
Presenter: Marc Denis
Session: Poster session 19
1361P - Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
Presenter: Shirish Gadgeel
Session: Poster session 19
1362P - Association of baseline (BL) anaplastic lymphoma kinase (ALK) fusion detected by circulating tumor DNA (ctDNA) with clinical features and outcomes in the phase III ALTA-3 trial
Presenter: Charu Aggarwal
Session: Poster session 19